Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant spastic paraplegia type 41 is a pure form of hereditary spastic paraplegia characterized by onset in adolescence or early adulthood of slowly progressive spastic paraplegia, proximal muscle weakness of the lower extremities and small hand muscles, hyperreflexia, spastic gait and mild urinary compromise.
Features include: Urinary urgency, Lower limb muscle weakness, Spastic gait, and Spastic paraplegia and 1 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 3 | Spastic gait, Spastic paraplegia, Overactive reflexes (hyperreflexia) |
Biomarker and diagnostic research for hereditary spastic paraplegia 41 has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for hereditary spastic paraplegia 41.
15 publications have been identified in PubMed for hereditary spastic paraplegia 41. Research spans Diagnostic / Biomarker (33%), Epidemiology / Natural History (33%), and Case Report / Case Series (20%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 5 | 33% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:55 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
1 |
Urinary urgency |
Muscles | 1 | Lower limb muscle weakness |
Arms and legs | 1 | Lower limb muscle weakness |
Disease patterns and progression
5 |
33% |
Patient case studies | 3 | 20% |
Research summaries | 1 | 7% |
New treatment approaches | 1 | 7% |
Resch D (2026). [PMID: 41328529](https://pubmed.ncbi.nlm.nih.gov/41328529/). *Movement disorders : official journal of the Movement Disorder Society*. [Epidemiology / Natural History]
Agianda HAP (2026). [PMID: 41365832](https://pubmed.ncbi.nlm.nih.gov/41365832/). *Movement disorders : official journal of the Movement Disorder Society*. [Diagnostic / Biomarker]
Israr S (2026). [PMID: 40856587](https://pubmed.ncbi.nlm.nih.gov/40856587/). *Journal of child neurology*. [Review / Meta-Analysis]
Zhang D (2026). [PMID: 41403389](https://pubmed.ncbi.nlm.nih.gov/41403389/). *Movement disorders : official journal of the Movement Disorder Society*. [Case Report / Case Series]
Zhu R (2026). [PMID: 41312619](https://pubmed.ncbi.nlm.nih.gov/41312619/). *Movement disorders : official journal of the Movement Disorder Society*. [Epidemiology / Natural History]
Toyoda N (2026). [PMID: 41503587](https://pubmed.ncbi.nlm.nih.gov/41503587/). *eNeurologicalSci*. [Case Report / Case Series]
Safka Brozkova D (2026). [PMID: 41749354](https://pubmed.ncbi.nlm.nih.gov/41749354/). *Human genomics*. [Diagnostic / Biomarker]
Erhardt C (2026). [PMID: 41774218](https://pubmed.ncbi.nlm.nih.gov/41774218/). *Metabolic brain disease*. [Epidemiology / Natural History]
Stevanin G (2025). [PMID: 41384654](https://pubmed.ncbi.nlm.nih.gov/41384654/). *Medecine sciences : M/S*. [Gene Therapy / Novel Therapeutics]
Penn D (2025). [PMID: 40470849](https://pubmed.ncbi.nlm.nih.gov/40470849/). *Movement disorders clinical practice*. [Diagnostic / Biomarker]